4JAM image
Deposition Date 2013-02-18
Release Date 2013-04-03
Last Version Date 2024-11-27
Entry Detail
PDB ID:
4JAM
Keywords:
Title:
Crystal structure of broadly neutralizing anti-hiv-1 antibody ch103
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.65 Å
R-Value Free:
0.19
R-Value Work:
0.16
R-Value Observed:
0.17
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:ANTIGEN BINDING FRAGMENT OF HEAVY CHAIN of CH103
Chain IDs:A (auth: H), C (auth: A)
Chain Length:226
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:ANTIGEN BINDING FRAGMENT OF LIGHT CHAIN of CH103
Chain IDs:B (auth: L), D (auth: B)
Chain Length:209
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation

Abstact

Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of HIV-1-infected individuals, and details of their generation could provide a blueprint for effective vaccination. Here we report the isolation, evolution and structure of a broadly neutralizing antibody from an African donor followed from the time of infection. The mature antibody, CH103, neutralized approximately 55% of HIV-1 isolates, and its co-crystal structure with the HIV-1 envelope protein gp120 revealed a new loop-based mechanism of CD4-binding-site recognition. Virus and antibody gene sequencing revealed concomitant virus evolution and antibody maturation. Notably, the unmutated common ancestor of the CH103 lineage avidly bound the transmitted/founder HIV-1 envelope glycoprotein, and evolution of antibody neutralization breadth was preceded by extensive viral diversification in and near the CH103 epitope. These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination.

Legend

Protein

Chemical

Disease

Primary Citation of related structures